Researchers found leukemias trending higher as the ‘baby boomer’ generation ages. Interestingly, incidence of all cancers was not correlated with the increase in older Americans.
Patients who received androgen therapy demonstrated improvements in erythroid, platelet, and neutrophil measures.
An Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM), but receiving medication orally is linked to higher satisfaction.
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
Researchers hypothesized that overlapping characteristics between autoimmune disease and NHL could be the result of similar genetic components.
An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
For patients receiving drug therapy, economic burden substantial across lines of therapy.
The antigen expression level on tumors that is necessary to engage and activate CAR-T cells is not currently known.
Although statistically insignificant, results of a randomized study determined the potential for nurse-led interventions as adjunct posttreatment care for lymphoma survivors.
Antibiotic treatment with carbapenem for S. aureus infection was efficacious in patients with cutaneous T-cell lymphomas.
A retrospective analysis suggests that monitoring MRD in early-stage follicular lymphoma may predict prognosis and guide rituximab therapy.
No data are available from randomized clinical trials comparing ibrutinib monotherapy with rituximab-based chemoimmunotherapy in Waldentrom Macroglobulinemia.
Tisagenlecleucel appeared to be safe and showed clinical activity in a small group of patients with secondary CNS lymphoma.
Results from a phase 2 trial suggest that adding lenalidomide to follicular lymphoma treatment with rituximab may be efficacious.
Researchers reported follow-up data for patients with advanced-stage Hodgkin lymphoma evaluated for response with positron emission tomography scanning.
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
A considerable proportion of patients with Waldenström macroglobulinemia experience disease-related adverse events, such as hyperviscosity and neuropathy.
Fiscal year 2020 Inpatient Prospective Payment System from CMS includes an increase in the reimbursement rate for CAR-T therapy; however, it falls short of suggestions ASH had submitted to the agency.
Further studies needed to look at relevance outside of the transplant-eligible population.